Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Corey

Showing results (131-140 of 222) with videos related to

Pageof 23
Sort By:
Biorxiv : the Preprint Server for Biology|June 19, 2023
A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulatorAnniek Zaalberg, Emma Minnee, Isabel Mayayo-Peralta, et al.
European Urology|June 23, 2019
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived XenograftsHung-Ming Lam, Holly M Nguyen, Mark P Labrecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived XenograftsHung-Ming Lam, Ryan McMullin, Holly M Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2017
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse ModelsMari I Suominen, Katja M Fagerlund, Jukka P Rissanen, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2024
Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogrammingYatian Yang, Xiong Zhang, Demin Cai, et al.
Neoplasia (New York, N.Y.)|May 14, 2020
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4Daniel J Coleman, David A Sampson, Archana Sehrawat, et al.
Cell Reports. Medicine|December 10, 2024
Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuitIlya S Senatorov, Joel Bowman, Keith H Jansson, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate CancerLisanne Mout, Thaidy Moreno-Rodriguez, Giacomo Grillo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 26, 2013
Prostate cancer cell phenotypes based on AGR2 and CD10 expressionMelissa E Ho, Sue-Ing Quek, Lawrence D True, et al.
The Prostate|October 5, 2023
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancerMark P Labrecque, Lisha G Brown, Ilsa M Coleman, et al.
Pageof 23

Showing results (131-140 of 222) with videos related to

Sort By:
Pageof 23
Biorxiv : the Preprint Server for Biology|June 19, 2023
A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulatorAnniek Zaalberg, Emma Minnee, Isabel Mayayo-Peralta, et al.
European Urology|June 23, 2019
Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived XenograftsHung-Ming Lam, Holly M Nguyen, Mark P Labrecque, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 21, 2016
Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived XenograftsHung-Ming Lam, Ryan McMullin, Holly M Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2017
Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse ModelsMari I Suominen, Katja M Fagerlund, Jukka P Rissanen, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 9, 2024
Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogrammingYatian Yang, Xiong Zhang, Demin Cai, et al.
Neoplasia (New York, N.Y.)|May 14, 2020
Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4Daniel J Coleman, David A Sampson, Archana Sehrawat, et al.
Cell Reports. Medicine|December 10, 2024
Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuitIlya S Senatorov, Joel Bowman, Keith H Jansson, et al.
Biorxiv : the Preprint Server for Biology|August 20, 2025
Genetic and Epigenetic Reprogramming of Transposable Elements Drives ecDNA-Mediated Metastatic Prostate CancerLisanne Mout, Thaidy Moreno-Rodriguez, Giacomo Grillo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 26, 2013
Prostate cancer cell phenotypes based on AGR2 and CD10 expressionMelissa E Ho, Sue-Ing Quek, Lawrence D True, et al.
The Prostate|October 5, 2023
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancerMark P Labrecque, Lisha G Brown, Ilsa M Coleman, et al.
Pageof 23